reviewed april 2026|next review october 2026|88 physicians psi has verified|69751 published studies
Lactoferricin
Lactoferricin is a 25-amino acid antimicrobial peptide released from the N-terminus of lactoferrin by pepsin cleavage during digestion, possessing antimicrobial activity more potent than the parent protein and demonstrated anticancer properties in cell studies.
Evidence landscape: 69751 published studies
Published studies span antimicrobial peptide research, cancer biology, and breast milk immunology. Consistent animal study data from multiple laboratories.
- 17 Human
- 137 Animal
- 46 Reviews
- 69551 Other research
Not FDA-approved as a therapeutic. Lactoferricin is a naturally occurring peptide released during digestion of lactoferrin. Lactoferrin supplements are available over the counter but no lactoferricin-specific therapeutic exists.
Not available as a standalone therapeutic product. Lactoferrin supplements (which release lactoferricin during digestion) are widely available over the counter. Whether supplement-level lactoferrin intake delivers meaningful lactoferricin to target tissues is not established.
Lactoferricin is part of the breast milk innate immune defense system. It is more potent than lactoferrin itself as an antimicrobial. Like LL-37 and defensins, it is being studied as a template for new antibiotics. The anticancer activity (through mitochondrial membrane targeting) distinguishes it from many other antimicrobial peptides.
PSI Assessment
Breast milk protects newborns from infection through multiple mechanisms, and one of the most potent is a small peptide called lactoferricin. Released when stomach acid cleaves the lactoferrin protein, lactoferricin kills bacteria, fungi, and viruses by punching holes in their membranes. It also shows selective toxicity toward cancer cells in laboratory studies. The antimicrobial activity is more potent than the parent lactoferrin protein. Like LL-37 and defensins, lactoferricin is being studied as a template for new antibiotics. The gap is clinical translation: no lactoferricin-specific therapeutic has been developed, and whether oral lactoferrin supplementation delivers meaningful levels to target tissues is not established.
Released from breast milk protein during digestion. More potent antimicrobial than lactoferrin itself. Selective anticancer activity in lab studies. No clinical therapeutic exists.
The mechanism involves electrostatic interaction between the cationic lactoferricin peptide and anionic microbial membranes, leading to membrane disruption and cell death. Additional mechanisms include iron chelation, LPS binding and endotoxin neutralization, and anti-biofilm activity. The anticancer mechanism involves mitochondrial membrane permeabilization, caspase activation, and inhibition of angiogenesis through VEGF downregulation. The selectivity for cancer cells over normal cells may relate to differences in membrane charge and composition.
What the evidence supports
Lactoferricin demonstrates broad-spectrum antimicrobial activity against bacteria, viruses, and fungi in laboratory studies, with potency exceeding the parent lactoferrin protein. The breast milk defense role is established. Anticancer activity through mitochondrial membrane permeabilization is documented in cell studies with selectivity toward cancer cells over normal cells. LPS-binding and endotoxin neutralization are confirmed.
What is not yet established
Clinical efficacy for any antimicrobial or anticancer indication. Whether the in vitro selectivity for cancer cells translates to in vivo therapeutic utility. Whether oral lactoferrin supplementation delivers meaningful lactoferricin levels to target tissues. Pharmacokinetics and delivery for systemic applications.
Research Evidence
The findings below cover the antimicrobial activity, the anticancer mechanism, and the breast milk immune defense context.
Evidence by condition
Evidence dimensions across antimicrobial, anticancer, and gut immunity research. All evidence is from animal studies. No clinical trials have been conducted for lactoferricin specifically.
| Condition | Mechanism | Animal evidence | Human evidence | Replication |
|---|---|---|---|---|
| Antimicrobial Defense | ||||
| Anticancer Biology | ||||
| Gut Immunity | ||||
| Infant Immune Defense |
Lactoferricin B (bovine, 25 amino acids, residues 17-41 of lactoferrin) demonstrates broad-spectrum antimicrobial activity against gram-positive and gram-negative bacteria, fungi, and some viruses, with potency exceeding the parent lactoferrin protein.
The antimicrobial activity is one of the most consistent findings in antimicrobial peptide research. Multiple independent laboratories have confirmed broad-spectrum activity.
Anticancer activity operates through a distinct mechanism: mitochondrial membrane permeabilization and caspase activation in cancer cells, with selectivity over normal cells in cell culture models.
The dual antimicrobial/anticancer activity distinguishes lactoferricin from many other antimicrobial peptides. Whether this selectivity holds in living organisms is untested.
Lactoferricin binds LPS (lipopolysaccharide) and neutralizes endotoxins, providing a distinct anti-inflammatory mechanism beyond direct antimicrobial killing.
Endotoxin neutralization is clinically relevant because bacterial toxins drive sepsis and systemic inflammation. This mechanism could have therapeutic value independent of direct bacterial killing.
17 Human|137 Animal|46 Reviews
View all 69751 indexed studiesHow Lactoferricin Works
Lactoferricin is a 25-amino acid cationic antimicrobial peptide released from bovine lactoferrin (residues 17-41) by pepsin cleavage. It disrupts microbial membranes through electrostatic and hydrophobic interactions, binds LPS, and targets cancer cell mitochondria.
When lactoferrin (from milk or supplements) is digested, stomach acid releases lactoferricin, a small peptide that punches holes in bacteria and fungi. It is part of the reason breast milk protects infants from infections before their immune systems are fully developed.
For a more detailed view of the biology, here is what researchers have observed at the molecular level.
Lactoferricin B is a 25-amino acid cationic peptide from bovine lactoferrin (residues 17-41). It disrupts microbial membranes via electrostatic interaction with anionic lipids. Additional mechanisms include iron chelation, LPS binding, and anti-biofilm activity. Anti-cancer activity involves membrane disruption and apoptosis induction.
What is Lactoferricin being studied for?
Researchers are studying Lactoferricin across several health conditions. Each condition below is labeled with the strength of evidence that exists for that specific use, not for Lactoferricin overall. This means a compound can have human studies for one condition but only animal data for another.
Antimicrobial Defense
·Human TrialsBroad-spectrum activity against bacteria, viruses, and fungi demonstrated in laboratory studies across multiple independent groups. More potent than the parent lactoferrin protein. Oral lactoferrin supplementation has shown immune benefits in some human studies.
Limitations: No lactoferricin-specific clinical trial has been conducted. Whether oral lactoferrin supplementation delivers meaningful lactoferricin levels to target tissues is not established.
Anticancer Biology
·Animal StudiesSelective cytotoxicity against cancer cells through mitochondrial membrane permeabilization and caspase activation in cell culture. Shows selectivity over normal cells in vitro.
Limitations: All data is from cell culture. The gap between in vitro cancer cell killing and clinical anticancer therapy is substantial. No animal tumor model data has validated the anticancer concept.
Gut Immunity
·Animal StudiesLactoferricin contributes to innate gut defense as part of the breast milk immune system. Lactoferrin supplementation has shown benefits in some infant immunity studies.
Limitations: Whether the gut immune benefits of lactoferrin supplementation are specifically mediated by lactoferricin release versus other lactoferrin mechanisms is not distinguished.
Infant Immune Defense
·Animal StudiesPart of the breast milk innate immune defense system. Released during digestion of lactoferrin. Contributes to neonatal protection against infection before the adaptive immune system matures.
Limitations: The breast milk defense role is established as part of lactoferrin biology broadly. Whether lactoferricin specifically (versus other lactoferrin-derived peptides and mechanisms) is the primary protective factor is not fully resolved.
Safety and Regulatory Status
FDA Status: Not FDA-approved as a therapeutic. Lactoferrin (the parent protein) is Generally Recognized as Safe as a food ingredient. Lactoferrin supplements are available over the counter.
Availability: Lactoferrin supplements are widely available. No standalone lactoferricin product exists. Lactoferricin is naturally produced during digestion of lactoferrin from milk.
Class context: Lactoferricin is present in digested milk with no safety concerns. The parent protein lactoferrin has Generally Recognized as Safe status. The natural production pathway (pepsin cleavage during digestion) is a normal physiological process.
Lactoferricin is naturally present in digested milk. Lactoferrin supplements are generally well tolerated with Generally Recognized as Safe status. No lactoferricin-specific safety concerns exist beyond the general antimicrobial peptide considerations at pharmacological doses.
Questions and Comparisons
Questions the evidence raises for a Lactoferricin discussion.
Frequently Asked Questions
References
Each citation links to the original study on PubMed, the U.S. National Library of Medicine database.
- 1.Foundational study identifying lactoferricin B (Lfcin B) as the antimicrobial fragment released from bovine lactoferrin during pepsin digestion. The 25-residue peptide demonstrated bactericidal activity against a broad spectrum of Gram-positive and Gram-negative bacteria at concentrations lower than the intact lactoferrin protein.Bellamy W et al., 1992 in Biochim Biophys Acta. View on PubMed
- 2.In vitro study demonstrating that bovine lactoferricin selectively induced apoptosis in human leukemia and carcinoma cell lines while sparing normal lymphocytes and fibroblasts. The selective cytotoxicity occurred through a mitochondrial-mediated pathway, positioning lactoferricin as a candidate for anti-cancer peptide research.Mader JS et al., 2005 in Mol Cancer Ther. View on PubMed
- 3.Comprehensive review of lactoferricin's multifunctional biological activities. Beyond direct antimicrobial effects, the peptide modulates immune responses by enhancing natural killer cell activity and macrophage function, and shows antiviral activity against herpes simplex virus and human cytomegalovirus.Gifford JL et al., 2005 in Cell Mol Life Sci. View on PubMed
- 4.Preclinical study showing that lactoferricin B inhibited lung cancer growth in mouse models through dual mechanisms: suppression of inflammatory cytokines and reduction of vascular endothelial growth factor (VEGF) expression. Tumor volume decreased significantly compared to controls, with reduced tumor angiogenesis.Yin CM et al., 2016 in J Dairy Sci. View on PubMed
Medical Disclaimer
This content is for educational and informational purposes only and does not constitute medical advice. The information presented reflects published research as indexed by PSI and should not be used to make treatment decisions. Always consult a qualified healthcare provider before starting, stopping, or modifying any treatment.